Benjamin Z. Stanton

Benjamin Z. Stanton's lab studies the molecular and genetic drivers of pediatric cancers, especially fusion-positive rhabdomyosarcoma, a childhood muscle cancer driven by an abnormal fusion protein (PAX3::FOXO1). The work focuses on how this fusion protein and related factors (like MYCN and SNAI2) rewire gene activity and chromatin (the packaging of DNA) to promote tumor growth, and explores potential drug targets such as chromatin-modifying enzymes and immune-based therapies like NK cell and CAR T-cell treatments. Overall, the research bridges cancer genetics, epigenetics (chemical modifications that control gene activity without changing DNA sequence), and translational efforts toward new sarcoma and leukemia therapies.

Publication output has grown from a handful of papers in 2017 to a steadier, higher rate of about 7-13 per year since 2021, indicating a generally increasing and now stable level of research activity over the past decade.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026